November 2014 - The Reporter
One of the largest simulation groups in the country will become two separate teams as of July 2022 to meet current and future growth: UAB Clinical Simulation for the Health System and the Office of Interprofessional Simulation for the academic campus.
Published in Campus News
You may be eligible to participate in a research study about the effects of sacubitril/valsartan on how your body handles insulin and glucose. This medication is related to the heart. Eligible participants must be healthy men and women, African American, and have no history of diabetes, heart problems, or kidney problems. The study involves performing some exercise, taking sacubitril/valsartan, and collecting blood samples. Participants will be compensated. To participate, please contact Nehal at 205-934-7173 or email us at nauticalstudy@uabmc.edu.
Published in Clinical Trials
You may be eligible to participate in a research study about the effects of Exercise and Metoprolol (a blood pressure pill) on a protein in your blood. This protein is related to heart disease. Eligible participants must be Healthy men and women, African American or Caucasians, and have no history of diabetes, heart problems, or kidney problems. The study involves performing the exercise, taking metoprolol, consuming prepared meals, and collecting blood samples. Participants will be compensated. Please e-mail Nehal Vekariya at exercisebetastudy@uabmc.edu or call us at 205-934-7173 if you are interested.
Published in Clinical Trials
Clinical trial evaluating a novel, non-invasive radiation treatment for ventricular tachycardia refractory to medication and catheter ablation The UAB Departments of Radiation Oncology and Cardiology are looking for patients with ventricular tachycardia (VT) not controlled by medications and catheter ablation. The trial will allow patients suffering from VT despite standard of care regimens to undergo non-invasive cardiac radioablation (CRA; a type of stereotactic body radiotherapy) to the area of the heart responsible for their symptoms. Stereotactic body radiotherapy is delivered with a device called the linear accelerator, which is primarily used to treat patients with cancer. UAB is one of the first centers in the U.S. to obtain a Food and Drug Administration (FDA) investigational device exemption for use of the linear accelerator in this capacity on a phase I/II trial. The study is being conducted in collaboration with the Washington University School of Medicine in St. Louis, a center which pioneered this promising technique in the U.S. For more information on the RAD 1901 trial, please contact Adelyn Gillon, clinical research coordinator, at 205.975.3019 or agillon@uabmc.edu" contenteditable="false">agillon@uabmc.edu.
Published in Clinical Trials
November 23, 2021

Asthma clinical trial

If you have asthma, are at least 18 years of age, in the Los Angeles Region, (California) haven’t had oral steroids in at least 4 weeks, and are willing to donate 30 mL of blood, equivalent to two tablespoons, please contact Racheal Ogbebor at email Rachealogbebor@gmail.com.
Published in Clinical Trials

The largest registry of U.S. children with cancer who were diagnosed with COVID-19 found an increased risk of having severe infection and having their cancer therapy modified because of COVID, underscoring the urgency of vaccinations for these children, the authors say.

Published in Research Findings

Shadi S. Martin, Ph.D., brings extensive experience in international and graduate education and a strong record of interdisciplinary scholarship to this new combined role.

Published in Leadership

For its work to promote bee conservation and growth on campus, UAB has been named a Bee Campus USA by Bee City USA, which recognizes, supports and encourages pollinator conservation in towns, cities and counties across the country.

Published in Sustainability

Help make the holidays merrier for Birmingham-area children by donating to two drives on campus this season — the annual UAB Toy Drive and Little Blazer Wishes.

Published in Get Involved
Clinical psychologist Aaron Fobian, Ph.D., has developed a therapy for this debilitating condition that she is now testing in a major NIH-sponsored clinical trial.
Published in Advances
Page 51 of 345